Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03360799
Other study ID # 2017-0568
Secondary ID NCI-2018-0102620
Status Completed
Phase
First received
Last updated
Start date November 17, 2017
Est. completion date August 26, 2019

Study information

Verified date August 2019
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This trial studies attitudes about legalization of marijuana use in participants with cancer. Questionnaires may help doctors to learn about and compare the attitudes that patients in non-legalized and legalized states have towards the legalization of medical marijuana.


Description:

PRIMARY OBJECTIVES:

I. To compare the proportion of cancer patients' who have a positive attitude about legalizing marijuana for medical purposes between those in a legalized versus (vs.) a non-legalized state.

SECONDARY OBJECTIVES:

I. To evaluate the association of cancer patients' belief in the usefulness of medical marijuana in their state of residency (Texas versus Arizona).

II. To examine the association of demographic, physical and psychosocial characteristics of patients and their perception of medical marijuana.

III. To examine the preference of patients for treatment of pain, anxiety and depression between medical marijuana vs. opioids, anti-anxiety and anti-depressant medications.

IV. To examine the association of media to perception of use of medical marijuana.

V. To evaluate the association of cancer patients' attitude about legalizing marijuana for medical purposes vs. recreational purposes.

VI. To examine the association of patients who have used marijuana for certain medical conditions/symptoms and their belief of how it has affected that condition/symptom.

VII. To compare demographic, physical and psychosocial characteristics of patients who have used marijuana for medical purposes.

VIII. To compare demographic, physical and psychosocial characteristics of patients who have used marijuana for non-medical purposes. IX. To compare demographic, physical and psychosocial characteristics of patients who believe marijuana is useful for medical reasons.

OUTLINE:

Participants complete 5 questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date August 26, 2019
Est. primary completion date August 26, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients (inpatient or outpatient) seen by the Palliative Care team at Banner MD Anderson or UT MD Anderson

- Patients able to speak and read English

- Patients enrolled in each site must be a resident of the state where that site is located (e.g. if a patient is enrolled at UT MD Anderson Cancer Center [MDACC], they should be resident of the state of Texas)

- Patients should have a cancer diagnosis

Exclusion Criteria:

- Patients who are not able to speak or read English

- Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaire Administration
Complete questionnaires

Locations

Country Name City State
United States Banner MD Anderson Cancer Center Gilbert Arizona
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive attitude regarding the legalization of medical marijuana for medical purposes Will be defined as answering "Completely Agree" or "Slightly Agree" to the question 1 in Marijuana Survey for Patients. The number of subjects with positive attitude towards legalizing medical marijuana will be compared between patients from Texas and Arizona States using one-sided Fisher's exact test or chi-squared test, whichever appropriate. A logistic model will be used to assess the effect of state of residency, adjusting for other covariates such as gender, age, race, etc. Will employ inverse probability of state weighting using the propensity score on all patients to estimate the difference in attitudes of marijuana use between the states. In the weighted sample, will also compute the standardized differences to evaluate the balance of baseline covariates between the two states. The propensity score model may be adjusted to further minimize some of the residual difference in the distribution of the baseline covariates between the two states. Up to 1 year
Secondary Participants' belief in the usefulness of medical marijuana between those who are residents of Texas versus Arizona The proportion of patients with positive belief will be reported with a 95% confidence interval. Fisher's exact test will be applied to compare the proportion between residents of two states. Up to 1 year
Secondary Perception of medical marijuana Will evaluate the association of demographical, physical, and psychosocial characteristics of patients and their perception of medical marijuana. In order to address this objective, all the specified characteristics will be summarized by descriptive statistics based on patients' perception of medical marijuana (positive or negative attitude); chi-square (or Fisher's exact) test and Wilcoxon rank sum test may be applied to test the associations for categorical and continuous variables, respectively. Logistic regression model may be utilized to evaluate the association of patients' characteristics with their perception of medical marijuana. Summarized reports of all other questions regarding the preference of patients for treatment of pain, anxiety and depression between medical marijuana versus opioids, anti-anxiety, anti-depressant medications, as well as the perception of impact of media on patient's preference in the Marijuana Survey for Patients will be provided. Up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT02243592 - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed NCT03445572 - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer N/A
Active, not recruiting NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Phase 2
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Completed NCT00026169 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Phase 1
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT01806129 - Reproductive Health Program in Patients With Cancer N/A
Recruiting NCT03915717 - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting NCT02280161 - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Terminated NCT00532064 - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed NCT04990882 - FAPI PET/CT Prospective Interobserver Agreement
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Completed NCT01506440 - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
Completed NCT01432431 - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff N/A